Hansa Biopharma AB (publ) (HNSBF) Income Statement Analysis

See more : Uzabase, Inc. (3966.T) Income Statement Analysis – Financial Results

Complete financial analysis of Hansa Biopharma AB (publ) (HNSBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hansa Biopharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Hansa Biopharma AB (publ) (HNSBF)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.hansabiopharma.com

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue	134.09M	154.53M	33.88M	6.10M	3.36M	3.36M	3.44M	2.58M	5.43M	4.72M	1.73M	2.62M	1.28M	4.45M	2.98M	103.68K
Cost of Revenue	63.14M	38.48M	15.43M	997.00K	866.00K	916.00K	221.00K	217.00K	658.00K	245.00K	317.96K	-2.49M	1.71M	0.00	0.00	0.00
Gross Profit	70.95M	116.05M	18.45M	5.10M	2.50M	2.44M	3.22M	2.36M	4.78M	4.47M	1.41M	5.11M	-432.44K	4.45M	2.98M	103.68K
Gross Profit Ratio	52.91%	75.10%	54.47%	83.65%	74.26%	72.72%	93.58%	91.59%	87.89%	94.80%	81.59%	194.96%	-33.73%	100.00%	100.00%	100.00%
Research & Development	411.33M	346.24M	230.76M	227.19M	192.95M	154.56M	137.06M	82.85M	44.26M	21.74M	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	450.49M	337.86M	327.27M	202.99M	167.31M	90.39M	43.72M	29.70M	28.24M	17.42M	11.26M	14.14M	21.16M	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	450.49M	337.86M	327.27M	202.99M	167.31M	90.39M	43.72M	29.70M	28.24M	17.42M	11.26M	14.14M	21.16M	0.00	0.00	0.00
Other Expenses	-2.38M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	859.45M	692.17M	558.03M	430.18M	360.09M	244.22M	179.34M	113.50M	70.98M	29.18M	19.05M	21.91M	27.46M	24.44M	18.72M	16.01M
Cost & Expenses	922.59M	730.65M	573.46M	431.18M	360.96M	245.14M	179.56M	113.71M	71.64M	29.43M	19.37M	19.43M	29.18M	24.44M	18.72M	16.01M
Interest Income	27.99M	8.83M	67.00K	388.00K	118.00K	52.00K	97.00K	23.00K	0.00	42.00K	93.22K	346.44K	47.78K	0.00	0.00	0.00
Interest Expense	105.52M	43.67M	694.00K	257.00K	466.00K	706.00K	695.00K	103.00K	65.00K	123.00K	15.76K	4.74K	155.41K	0.00	0.00	0.00
Depreciation & Amortization	19.79M	12.05M	8.61M	7.55M	6.91M	1.84M	3.78M	3.45M	989.00K	1.35M	96.65K	126.79K	-52.36M	0.00	381.77K	415.40K
EBITDA	-705.50M	-554.26M	-538.83M	-414.75M	-351.66M	-245.47M	-172.23M	-107.60M	-65.21M	-24.48M	-17.45M	-16.27M	-24.29M	-19.99M	-15.36M	-15.47M
EBITDA Ratio	-526.12%	-355.47%	-1,588.95%	-6,801.44%	-10,466.94%	-7,284.69%	-5,004.68%	-4,174.49%	-1,200.07%	-494.44%	-1,010.39%	-623.73%	-2,175.42%	-449.46%	-514.75%	-14,925.86%
Operating Income	-788.50M	-588.59M	-546.98M	-422.81M	-359.67M	-246.50M	-176.08M	-111.14M	-66.20M	-24.71M	-17.64M	-16.81M	24.46M	-19.99M	-15.74M	-15.91M
Operating Income Ratio	-588.02%	-380.90%	-1,614.55%	-6,933.54%	-10,691.68%	-7,340.62%	-5,115.72%	-4,309.23%	-1,218.27%	-523.94%	-1,021.38%	-641.80%	1,907.97%	-449.46%	-527.54%	-15,341.72%
Total Other Income/Expenses	-42.32M	-33.86M	-1.15M	1.91M	-2.00M	-6.24M	-616.00K	-17.00K	-65.00K	-4.33M	67.00K	331.97K	-107.63K	-150.48K	-71.60K	16.52M
Income Before Tax	-830.81M	-609.98M	-548.13M	-420.89M	-359.59M	-248.01M	-176.70M	-111.15M	-66.27M	-29.04M	-17.56M	-16.47M	-24.57M	-20.14M	-15.81M	616.70K
Income Before Tax Ratio	-619.57%	-394.74%	-1,617.95%	-6,902.15%	-10,689.42%	-7,385.77%	-5,133.61%	-4,309.89%	-1,219.47%	-615.82%	-1,016.90%	-628.75%	-1,916.36%	-452.84%	-529.94%	594.83%
Income Tax Expense	908.00K	1.16M	152.00K	-40.00K	417.00K	-40.00K	-39.00K	-23.00K	0.00	42.00K	93.22K	346.44K	65.00	-1.30M	0.00	3.17M
Net Income	-831.72M	-611.13M	-548.28M	-420.85M	-360.01M	-247.97M	-176.66M	-111.13M	-66.27M	-29.04M	-17.56M	-16.47M	-24.57M	-18.84M	-15.81M	-2.56M
Net Income Ratio	-620.25%	-395.49%	-1,618.40%	-6,901.49%	-10,701.81%	-7,384.57%	-5,132.48%	-4,309.00%	-1,219.47%	-615.82%	-1,016.90%	-628.75%	-1,916.37%	-423.62%	-529.94%	-2,467.50%
EPS	-15.83	-13.60	-12.33	-9.98	-9.00	-6.47	-4.97	-3.37	-2.12	-1.09	-0.72	-0.71	-2.11	-2.27	-3.12	-0.51
EPS Diluted	-15.83	-13.60	-12.33	-9.98	-9.00	-6.47	-4.96	-3.37	-2.12	-1.09	-0.72	-0.71	-2.11	-2.27	-3.12	-0.51
Weighted Avg Shares Out	52.54M	44.92M	44.47M	42.18M	40.02M	38.33M	35.52M	33.01M	31.21M	26.54M	24.54M	23.24M	11.64M	8.31M	5.06M	5.00M
Weighted Avg Shares Out (Dil)	52.54M	44.92M	44.47M	42.18M	40.02M	38.33M	35.61M	33.01M	31.21M	26.54M	24.54M	23.24M	11.64M	8.31M	5.06M	5.00M

Hansa Biopharma half year report 2023

July 20, 2023prnewswire.com

Solid product sales in Q2 2023 Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome New Eurotransplant desensitization program implemented in June First patient treated in new investigator-initiated Phase 2 study in ANCA-associated vasculitis LUND, Sweden , July 20, 2023...

Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Call Transcript

February 4, 2023seekingalpha.com

Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Søren Tulstrup - President and CEO Donato Spota - SVP and CFO Conference Call Participants Gonzalo Attali - ABG Sundal Collier Zoe...

Hansa Biopharma AB (HNSBF) Q3 2022 Earnings Call Transcript

October 20, 2022seekingalpha.com

Hansa Biopharma AB (OTCPK:HNSBF) Q3 2022 Earnings Conference Call October 20, 2022 8:00 AM ET Company Participants Soren Tulstrup - President and Chief Executive Officer Donato Spota - Senior Vice President, Chief Financial Officer Conference Call Participants Christopher Uhde -...

Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update

September 30, 2022prnewswire.com

LUND, Sweden , Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022.

Hansa Biopharma AB (publ) (HNSBF) CEO Søren Tulstrup on Q2 2022 Results - Earnings Call Transcript

July 19, 2022seekingalpha.com

Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q2 2022 Earnings Conference Call July 19, 2022 8:00 AM ET Company Participants Søren Tulstrup - CEO Donato Spota - CFO Conference Call Participants Dominic Rose - Intron Health Research Douglas Tsao - H.C. Wainwright...

Hansa Biopharma AB's (HNSBF) CEO Søren Tulstrup on Q1 2022 Results - Earnings Call Transcript

April 21, 2022seekingalpha.com

Hansa Biopharma AB (publ) ( OTC:HNSBF ) Q1 2022 Earnings Conference Call April 21, 2022 8:00 AM ET Company Participants Søren Tulstrup – Chief Executive Officer Conference Call Participants Adam Karlsson – ABG Douglas Tsao – H.C. Wainwright Christopher Uhde...